Stock comparison
ResMed
Stryker
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.31B
Sector
Healthcare
SYK
Stryker
Market cap
$121.8B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | SYK | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 65B | RMD |
| Benjamin Graham | 75B | 83A | SYK |
| Philip Fisher | 75B | 67C | RMD |
| Peter Lynch | 58C | 68B | SYK |
| Joel Greenblatt | 47D | 50D | SYK |
| Charlie Munger | 69B | 63D | RMD |
| Terry Smith | 73B | 62D | RMD |
Side-by-side metrics
| Metric | RMD | SYK |
|---|---|---|
| Market cap | $30.31B | $121.8B |
| P/E (TTM) | 19.6x | 35.2x |
| EV/EBIT | 17.1x | 26.4x |
| ROIC (TTM) | 19.63% | 9.79% |
| Gross margin | 61.69% | 63.67% |
| Net margin | 27.44% | 13.21% |
| Revenue CAGR 5y | 12.64% | 10.07% |
| EPS CAGR 5y | 30.73% | 12.55% |
| Debt / Equity | 0.1x | 0.6x |
| Dividend yield | 1.14% | 1.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Debt / Equity0.1xvs 0.6x+80%
- EPS CAGR 5y30.73%vs 12.55%+59%
- Net margin27.44%vs 13.21%+52%
- ROIC (TTM)19.63%vs 9.79%+50%
SYK leads on
- Market cap$121.8Bvs $30.31B+75%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.